Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Riot Platforms Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287.91 (market cap $39.89B), while Riot Platforms Inc trades at $19.89 (market cap $7.93B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 5× Riot Platforms Inc's market cap, and Riot Platforms Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | RIOT | |
|---|---|---|
Market Cap | $39.89B | $7.93B |
Sector | Health | Technology |
52-Week High | $491.22 | $28.67 |
52-Week Low | $278.09 | $11.03 |
Enterprise Value | $38.15B | $8.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
RIOT trades at $20.97, down 2.58% today, with a bearish technical signal. Recent earnings show mixed results, beating in Q3 2025 but missing in Q4 2025 and Q1 2026. The company reported a net loss of $663 million in 2025 despite $647 million revenue. Analyst consensus is strongly bullish with a $27.86 price target. News highlights volatility tied to Bitcoin trends and a strategic pivot toward AI data centers.
Outlook remains speculative with high valuation multiples amid persistent losses. Opportunities include expansion into high-performance computing, but risks involve cash flow deficits, competitive pressures, and sensitivity to cryptocurrency markets. Investors should weigh analyst optimism against fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
